| P&L Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 120 | 177 | 235 | 276 |
| Cost of Material Consumed | 49.4 | 92 | 140 | 172 |
| Change in Inventory | 2 | -4 | -1 | 1 |
| Gross Margins | 57.17 | 50.28 | 40.85 | 37.32 |
| Employee Benefit Expenses | 35 | 35 | 38 | 36 |
| Other Expenses | 14.4 | 13 | 16 | 21 |
| EBITDA | 19.2 | 41 | 42 | 46 |
| OPM | 16 | 23.16 | 17.87 | 16.67 |
| Other Income | 24.9 | 30 | 46 | 0.5 |
| Finance Cost | 0.1 | 0.6 | 0.64 | 0.45 |
| D&A | 2.6 | 5 | 6.3 | 5.78 |
| EBIT | 16.6 | 36 | 35.7 | 40.22 |
| EBIT Margins | 13.83 | 20.34 | 15.19 | 14.57 |
| PBT | 47 | 65 | 80 | 40 |
| PBT Margins | 39.17 | 36.72 | 34.04 | 14.49 |
| Tax | 9.2 | 14 | 17 | 8 |
| PAT | 37.8 | 51 | 63 | 32 |
| NPM | 31.5 | 28.81 | 26.81 | 11.59 |
| EPS | 47.25 | 63.75 | 77.97 | 39.6 |
Financial Ratios |
2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Operating Profit Margin | 16 | 23.16 | 17.87 | 16.67 |
| Net Profit Margin | 31.5 | 28.81 | 26.81 | 11.59 |
| Earning Per Share (Diluted) | 47.25 | 63.75 | 77.97 | 39.6 |
| Assets | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Fixed Assets | 13.7 | 16 | 16 | 15 |
| CWIP | 0.3 | 0 | 0.18 | 0 |
| Investments | 178.6 | 220 | 269 | 479 |
| Trade Receivables | 52.4 | 37 | 21 | 57 |
| Inventory | 0 | 4 | 4.6 | 4 |
| Other Assets | 272.8 | 306 | 376.22 | 180 |
| Total Assets | 517.8 | 583 | 687 | 735 |
| Liabilities | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Share Capital | 8 | 8 | 8.08 | 8.08 |
| FV | 10 | 10 | 10 | 10 |
| Reserves | 462 | 512 | 574 | 606 |
| Borrowings | 0 | 0 | 0 | 0 |
| Trade Payables | 9 | 16 | 15 | 67.5 |
| Other Liabilities | 38.9 | 47 | 89.92 | 53.42 |
| Total Liabilities | 517.9 | 583 | 687 | 735 |
| Cash-Flow Statement | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| PBT | 41 | 65 | 76 | 84 |
| OPBWC | 19.2 | 45 | 48 | 56 |
| Change in Receivables | -20.7 | 12 | 9.67 | -44.52 |
| Change in Inventories | 2.2 | -4 | -0.53 | 0.72 |
| Change in Payables | 3.2 | 7 | 1.43 | 29.46 |
| Other Changes | -1.7 | -9 | 42.43 | -62.66 |
| Working Capital Change | -17 | 6 | 53 | -77 |
| Cash Generated From Operations | 2.2 | 51 | 101 | -21 |
| Tax | -8 | -6 | -18 | -15 |
| Cash Flow From Operations | -5.8 | 45 | 83 | -36 |
| Purchase of PPE | -0.9 | -5 | -1.68 | -6 |
| Sale of PPE | 0 | 0 | 0 | 0 |
| Cash Flow From Investment | -6.9 | -43 | -67 | 47 |
| Borrowing | 0 | 0 | 0 | 0 |
| Dividend | -0.8 | -1 | -1.61 | -2.02 |
| Equity | 0 | 0 | 0 | 0 |
| Others From Financing | -0.2 | -2 | -1.39 | -1.98 |
| Cash Flow from Financing | -1 | -3 | -3 | -4 |
| Net Cash Generated | -13.7 | -1 | 13 | 7 |
| Cash at the Start | 18.7 | 5 | 4 | 17 |
| Cash at the End | 5 | 4 | 17 | 24 |
| Name | Designation | Experience | Linkedin Profile |
|---|---|---|---|
| Anil Kakodkar | Chairman | 40 yrs |
|
| Veena Kamath | MD | 23 Yrs |
|
| Komal Chaubal | CEO & CS | 20 Yrs |
|